14-3-3 adaptor protein-protein interactions as therapeutic targets for CNS diseases

被引:48
|
作者
Kaplan, Andrew [1 ]
Ottmann, Christian [2 ,3 ,4 ]
Fournier, Alyson E. [1 ]
机构
[1] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[2] Eindhoven Univ Technol, Lab Chem Biol, Dept Biomed Engn, Eindhoven, Netherlands
[3] Eindhoven Univ Technol, Inst Complex Mol Syst, Eindhoven, Netherlands
[4] Univ Duisburg Essen, Dept Chem, Duisburg, Germany
基金
加拿大健康研究院;
关键词
14-3-3; Axon; Parkinson's; LRRK2; Neurodegeneration; Fusicoccin; Drug; SMALL-MOLECULE STABILIZATION; TAU-PROTEIN; MOUSE MODEL; DEFECTS; BINDING; LRRK2; INHIBITION; MICE; PHOSPHORYLATION; 14-3-3-EPSILON;
D O I
10.1016/j.phrs.2017.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
14-3-3s are a family of ubiquitously expressed adaptor proteins that regulate hundreds of functionally diverse 'client proteins.' In humans, there are seven isoforms with conserved structure and function. 14-3-3s typically bind to client proteins at phosphorylated serine/threonine motifs via a linear binding groove. Binding can have a variety of effects on the stability, activity and/or localization of the client protein. 14-3-3s are generating significant interest as potential drug targets for their involvement in cellular homeostasis and disease. They are especially abundant in the central nervous system (CNS) and are implicated in numerous CNS diseases, often through specific interactions with disease-relevant client proteins. Several tool compounds that can modulate 14-3-3 interactions with client proteins to elicit therapeutic effects have recently been described. Here we offer a perspective on the functions of 14-3-3s in neurons and the potential development of drugs to therapeutically target 14-3-3 PPIs for CNS diseases. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:114 / 121
页数:8
相关论文
共 50 条
  • [21] From Tethered to Freestanding Stabilizers of 14-3-3 Protein-Protein Interactions through Fragment Linking
    Visser, Emira J.
    Jaishankar, Priyadarshini
    Sijbesma, Eline
    Pennings, Marloes A. M.
    Vandenboorn, Edmee M. F.
    Guillory, Xavier
    Neitz, R. Jeffrey
    Morrow, John
    Dutta, Shubhankar
    Renslo, Adam R.
    Brunsveld, Luc
    Arkin, Michelle R.
    Ottmann, Christian
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2023, 62 (37)
  • [22] Rationally Designed Semisynthetic Natural Product Analogues for Stabilization of 14-3-3 Protein-Protein Interactions
    Andrei, Sebastian A.
    de Vink, Pim
    Sijbesma, Eline
    Han, Ling
    Brunsveld, Luc
    Kato, Nobuo
    Ottmann, Christian
    Higuchi, Yusuke
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (41) : 13470 - 13474
  • [23] Modulating GPCR and 14-3-3 protein interactions: Prospects for CNS drug discovery
    Kongsamut, Sathapana
    Eishingdrelo, Haifeng
    DRUG DISCOVERY TODAY, 2023, 28 (08)
  • [24] 14-3-3 Protein-Protein Interactions: From Mechanistic Understanding to Their Small-Molecule Stabilization
    Somsen, Bente A.
    Cossar, Peter J.
    Arkin, Michelle R.
    Brunsveld, Luc
    Ottmann, Christian
    CHEMBIOCHEM, 2024, 25 (14)
  • [25] Protein-protein interactions as therapeutic targets in neuropsychopharmacology
    Reilly, Matthew T.
    Cunningham, Kathryn A.
    Natarajan, Amarnath
    NEUROPSYCHOPHARMACOLOGY, 2009, 34 (01) : 247 - 248
  • [26] Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02
    Iralde-Lorente, Leire
    Cau, Ylenia
    Clementi, Letizia
    Franci, Lorenzo
    Tassone, Giusy
    Valensin, Daniela
    Mori, Mattia
    Angelucci, Adriano
    Chiariello, Mario
    Botta, Maurizio
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 657 - 664
  • [27] Fragment-Based Interrogation of the 14-3-3/TAZ Protein-Protein Interaction
    Andlovic, Blaz
    Valenti, Dario
    Centorrino, Federica
    Picarazzi, Francesca
    Hristeva, Stanimira
    Hiltmann, Malgorzata
    Wolf, Alexander
    Cantrelle, Francois-Xavier
    Mori, Mattia
    Landrieu, Isabelle
    Levy, Laura M.
    Klebl, Bert
    Tzalis, Dimitrios
    Genski, Thorsten
    Eickhoff, Jan
    Ottmann, Christian
    BIOCHEMISTRY, 2024, 63 (17) : 2196 - 2206
  • [28] A new class of supramolecular ligands stabilizes 14-3-3 protein-protein interactions by up to two orders of magnitude
    Gigante, A.
    Grad, J. -N.
    Briels, J.
    Bartel, M.
    Hoffmann, D.
    Ottmann, C.
    Schmuck, C.
    CHEMICAL COMMUNICATIONS, 2019, 55 (01) : 111 - 114
  • [29] Discovery of Small-Molecule Stabilizers of 14-3-3 Protein-Protein Interactions via Dynamic Combinatorial Chemistry
    Hartman, Alwin M.
    Elgaher, Walid A. M.
    Hertrich, Nathalie
    Andrei, Sebastian A.
    Ottmann, Christian
    Hirsch, Anna K. H.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (05): : 1041 - 1046
  • [30] Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions
    Valensin, Daniela
    Cau, Ylenia
    Calandro, Pierpaolo
    Vignaroli, Giulia
    Dello Iacono, Lucia
    Chiariello, Mario
    Mori, Mattia
    Botta, Maurizio
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) : 894 - 898